Rebamipide enemas-new effective treatment for patients with corticosteroid dependent or resistant ulcerative colitis.

Abstract

In this study we investigated the effect of rebamipide enema in patients with steroid-resistant and/or dependent ulcerative colitis. Rebamipide enemas were administered twice daily for a 12-week period; this treatment was further continued longer in patients who requested this. Disease activity index as reflecting the clinical condition and endoscopic index with histological grading were determined before and after the treatment period. Nine of 11 (81.8%) patients on 12-week treatment with rebamipide approved and were classified as colitis in remission. Moreover, seven of 11 patients requested long-term medication, the longest medication term being 80 weeks. These results medicated that rebamipide enemas may be effective in patients with steroid-resistant and/or dependent ulcerative colitis.

• Authors: Mitsuki Miyata, Kunio Kasugai, Tetsuya Ishikawa, Shinichi Kakumu, Masafumi Onishi, Takeshi Mori
• Journal: Digestive diseases and sciences (Dig Dis Sci) Vol. 50 Suppl 1 Pg. S119-23 (Oct 2005) ISSN: 0163-2116 [Print] United States
• PMID: 16184413 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Adrenal Cortex Hormones
• Anti-Ulcer Agents
• Quinolones
• rebamipide
• Alanine

Topics

• Adolescent
• Adrenal Cortex Hormones (pharmacology)
• Adult
• Alanine (administration & dosage, analogs & derivatives, therapeutic use)
• Anti-Ulcer Agents (administration & dosage, therapeutic use)
• Colitis, Ulcerative (drug therapy, pathology)
• Drug Resistance
• Enema
• Female
• Humans
• Male
• Middle Aged
• Patient Satisfaction
• Quinolones (administration & dosage, therapeutic use)
• Severity of Illness Index